1 reports of this reaction
5.9% of all PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT reports
#12 most reported adverse reaction
PRODUCT FORMULATION ISSUE is the #12 most commonly reported adverse reaction for PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT, manufactured by Oystershell Consumer Health Inc. There are 1 FDA adverse event reports linking PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT to PRODUCT FORMULATION ISSUE. This represents approximately 5.9% of all 17 adverse event reports for this drug.
Patients taking PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT who experience product formulation issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT FORMULATION ISSUE is moderately reported among PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT users, representing a notable but not dominant share of adverse events.
In addition to product formulation issue, the following adverse reactions have been reported for PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT:
The following drugs have also been linked to product formulation issue in FDA adverse event reports:
PRODUCT FORMULATION ISSUE has been reported as an adverse event in 1 FDA reports for PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT FORMULATION ISSUE accounts for approximately 5.9% of all adverse event reports for PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT, making it a notable side effect.
If you experience product formulation issue while taking PIPERONYL BUTOXIDE, PYRETHRUM EXTRACT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.